Aktis Oncology Gains FDA Clearance for Phase 1B Tumor Treatment Trial
summarizeSummary
Aktis Oncology has received FDA clearance for its Investigational New Drug (IND) application for AKY-2519, a miniprotein radioconjugate targeting a gene expressed in various tumors. This approval allows the company to proceed with a Phase 1b clinical trial, which is expected to commence in mid-2026. This regulatory advancement is a significant positive step for the company's pipeline, de-risking its development path for a potential new cancer treatment. The company also reported a widened 2025 loss of $63.7 million due to increased R&D expenses, but highlighted a strong cash position of $226.8 million, supplemented by $335.3 million from a January IPO, which is expected to fund operations into 2029. This robust financial runway provides stability for continued drug development following the positive regulatory news.
At the time of this announcement, AKTS was trading at $16.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $912.5M. The 52-week trading range was $14.72 to $24.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.